Benefits
Serum testosterone rose as a secondary marker in two muscle-strength trials
Two published randomized, double-blind, placebo-controlled trials in young men (ages 18 to 40) measured muscle strength as the primary outcome and serum testosterone as a secondary marker. In both, free and total testosterone rose versus placebo. These are secondary hormone readings in young, healthy men, not a measured sexual or clinical testosterone-deficiency outcome, and the specific figures sometimes quoted (a 19 percent total and 30 to 40 percent free testosterone rise in men aged 40 to 65 at 325 mg/day) do not appear in either published trial.
Muscle endurance and time to exhaustion
The two cited trials measured endurance: the Rokkam 2023 trial found greater treadmill time to exhaustion and more repetitions versus placebo, and the Salter 2024 trial found added repetitions to failure over resistance training alone. No published trial has measured sexual desire, frequency of activity, or sexual pleasure for this blend, so no sexual-function claim can be supported.
Fatigue and energy were not measured
Neither published trial of this blend measured mental or physical fatigue, so a fatigue or energy benefit cannot be supported. The measured human outcomes are muscle strength and endurance in young men.
Grip strength improvement
Handgrip strength improved versus placebo in the Rokkam 2023 trial (p < 0.001) in young men taking 650 mg/day for 56 days. This is an objective strength measure alongside the trial's other muscle outcomes (bench press, leg press, endurance).
Mechanism of action
Proposed testosterone-biosynthesis pathway (preclinical)
A proposed mechanism, established only in preclinical work and not confirmed in humans, is that Sphaeranthus indicus sesquiterpene lactones influence luteinizing hormone signaling while Mangifera indica polyphenols such as mangiferin affect steroidogenic enzyme activity in Leydig cells. The human trials of this blend recorded serum testosterone only as a secondary marker and did not test this pathway, so the LH and CYP11A1 steps remain unproven for the ingredient as sold.
Clinical trials
Randomized, double-blind, placebo-controlled trial of the Sphaeranthus indicus and Mangifera indica blend (the TestFACTOR/RipFACTOR blend). (Rokkam et al. 2023, Food & Nutrition Research)
Young male volunteers.
The blend significantly increased muscle strength and endurance versus placebo; TestFACTOR uses the same standardized blend.
Randomized, blinded, placebo-controlled trial of the Mangifera indica and Sphaeranthus indicus blend combined with resistance training. (Salter et al. 2024, Frontiers in Nutrition)
Young men in a resistance-training program.
Adding the blend improved muscle strength and endurance beyond exercise alone.